Clinical trial
A Randomized, Open-label, Controlled, Multiple Dose, Safety, Pharmacokinetic, and Pharmacodynamic Study of PLS240 in Pediatric Participants 1 Month to <18 Years of Age With Secondary Hyperparathyroidism and Chronic Kidney Disease Receiving Maintenance Hemodialysis
NCT07890584 is registered in ClinicalTrials.gov with Pathalys Pharma as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, 14-day trial. Card required. Your first charge is when the trial ends. See pricing
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Randomized, Open-label, Controlled, Multiple Dose, Safety, Pharmacokinetic, and Pharmacodynamic Study of PLS240 in Pediatric Participants 1 Month to <18 Years of Age With Secondary Hyperparathyroidism and Chronic Kidney Disease Receiving Maintenance Hemodialysis
- Lead sponsor
- Pathalys Pharma
- Phase
- Phase 3
- Overall status
- Not yet recruiting
- Start date
- October 30, 2026
- Completion date
- February 22, 2032
- Enrollment
- 56 (estimated)
- Sites
- 1
Conditions
As the registry lists them; a condition with its own page is linked.
chronic kidney disease (ckd), secondary hyperparathyroidism
Arms
As registered; 3 arms.
-
Cohort 1
Adolescents aged ≥13 to \<18 years. The study will initially only recruit participants into the older age group (Cohort 1). Participants will receive PLS240 plus standard of care.
-
Cohort 2
Children aged 1 month to \<13 years. Once safety and Pharmacokinetic (PK)/Pharmacodynamic (PD) data from 15 evaluable participants from Cohort 1 have been reviewed by a Safety Review Committee (SRC), recruitment into the younger (infants, toddlers, and children) age group will commence. Participants will receive PLS240 plus standard of care.
-
Control Group
Participants will only receive standard of care
Primary endpoints
Registered primary outcome measures; 1 primary.
-
Incidence of treatment-emergent adverse events (TEAEs).
Lead sponsor's other trials
Pathalys Pharma, most recent start first.
Similar trials
Same condition (Hyperparathyroidism, Secondary) and phase, most recent start first.
+35 more trials See the condition page